Protalix BioTherapeutics Receives Positive EMA Recommendation for New Elfabrio Dosage, Faces Financial Challenges

Protalix BioTherapeutics has received a positive recommendation from the European Medicines Agency's CHMP for a new dosing schedule of Elfabrio. The company operates in the biotechnology sector and has a market capitalization of $181.33 million. Protalix has faced challenges in maintaining revenue growth and has a distressing Altman Z-Score. The stock is trading at a premium compared to its historical ranges, with a P/E ratio of 32.21 and a P/B ratio of 3.42. Analyst targets set a target price of $12.5, indicating potential upside from current levels.